aztreonam has been researched along with Osteomyelitis in 11 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Osteomyelitis: INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aztreonam seems to be an effective single agent therapy for many bacterial infections." | 5.27 | Evaluation of aztreonam in the treatment of severe bacterial infections. ( Bouza, E; García de la Torre, M; Guerrero, A; Hellín, T; Martínez-Beltrán, J; Rodríguez-Créixems, M; Romero-Vivas, J, 1985) |
| " Dosage of aztreonam was 2 to 8 g per day administered intravenously or intramuscularly for five to 52 days." | 2.66 | Aztreonam in the treatment of serious orthopedic infections. ( Beskin, J; Beville, R; Haddad, RJ; Holmes, B; Mogabgab, WJ; Pollock, B; Pribyl, C; Salzer, R, 1985) |
| "Aztreonam was used for a year to treat 106 hospitalized patients with a total of 131 documented gram-negative infections." | 1.27 | Treatment of serious gram-negative infections with aztreonam. ( Bollinger, M; Darji, TB; Greenberg, RN; Luppen, KL; McMillian, R; Noorani, AA; Reilly, PM; Wolk, SM, 1984) |
| "Aztreonam seems to be an effective single agent therapy for many bacterial infections." | 1.27 | Evaluation of aztreonam in the treatment of severe bacterial infections. ( Bouza, E; García de la Torre, M; Guerrero, A; Hellín, T; Martínez-Beltrán, J; Rodríguez-Créixems, M; Romero-Vivas, J, 1985) |
| "Aztreonam is a novel antimicrobial agent belonging to the monobactam class of antibiotics." | 1.27 | Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. ( Neu, HC; Scully, BE, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, J | 1 |
| Zhou, S | 1 |
| Gu, H | 1 |
| Tong, K | 1 |
| Mularoni, A | 1 |
| Mezzatesta, ML | 1 |
| Pilato, M | 1 |
| Medaglia, AA | 1 |
| Cervo, A | 1 |
| Bongiorno, D | 1 |
| Aprile, A | 1 |
| Luca, A | 1 |
| Stefani, S | 1 |
| Grossi, P | 1 |
| Mittal, J | 1 |
| Szymczak, WA | 1 |
| Guo, Y | 1 |
| Levi, MH | 1 |
| Chen, L | 1 |
| Kreiswirth, BN | 1 |
| Riska, PF | 1 |
| Nori, P | 1 |
| Djalilian, HR | 1 |
| Shamloo, B | 1 |
| Thakkar, KH | 1 |
| Najme-Rahim, M | 1 |
| Greenberg, RN | 2 |
| Reilly, PM | 1 |
| Luppen, KL | 1 |
| McMillian, R | 1 |
| Bollinger, M | 1 |
| Wolk, SM | 1 |
| Darji, TB | 1 |
| Noorani, AA | 1 |
| Norden, CW | 1 |
| Budinsky, A | 1 |
| Smith, DW | 1 |
| Wilson, RD | 1 |
| Perry, CR | 1 |
| Ellington, LL | 1 |
| Becker, A | 1 |
| Vossen, MK | 1 |
| Burdge, RE | 1 |
| Romero-Vivas, J | 1 |
| Rodríguez-Créixems, M | 1 |
| Bouza, E | 1 |
| Hellín, T | 1 |
| Guerrero, A | 1 |
| Martínez-Beltrán, J | 1 |
| García de la Torre, M | 1 |
| Pribyl, C | 1 |
| Salzer, R | 1 |
| Beskin, J | 1 |
| Haddad, RJ | 1 |
| Pollock, B | 1 |
| Beville, R | 1 |
| Holmes, B | 1 |
| Mogabgab, WJ | 1 |
| Scully, BE | 1 |
| Neu, HC | 1 |
1 trial available for aztreonam and Osteomyelitis
| Article | Year |
|---|---|
Aztreonam in the treatment of serious orthopedic infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infections; Clinical | 1985 |
10 other studies available for aztreonam and Osteomyelitis
| Article | Year |
|---|---|
Meropenem-loaded Cement Is Effective in Preventing Gram-negative Osteomyelitis in an Animal Model.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bone Cements; Ceftazidime; Ciprofloxacin; Escherichia col | 2023 |
Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Ceftazidime; Debridement; Dr | 2021 |
Two for the price of one: emerging carbapenemases in a returning traveller to New York City.
Topics: Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; Ceftazidim | 2018 |
Treatment of culture-negative skull base osteomyelitis.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aztreonam; Ceftazidi | 2006 |
Treatment of serious gram-negative infections with aztreonam.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Drug Evaluation; En | 1984 |
Aztreonam therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.
Topics: Animals; Aztreonam; Osteomyelitis; Pseudomonas Infections; Rabbits | 1988 |
Treatment of Pseudomonas aeruginosa osteomyelitis with aztreonam.
Topics: Adult; Aztreonam; Female; Humans; Osteomyelitis; Pseudomonas Infections | 1987 |
Antibiotic stability in an implantable pump.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Clindamycin; Drug Stability; Gentamicins; Humans; Infusi | 1986 |
Evaluation of aztreonam in the treatment of severe bacterial infections.
Topics: Adolescent; Adult; Aged; Aztreonam; Bacterial Infections; Child; Humans; Middle Aged; Osteomyelitis; | 1985 |
Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infectio | 1985 |